Dear Editor,
It is important that randomized clinical trials (RCTs), as the most valuable research method for assessing the efficacy of treatments, are reported with the highest possible level of quality (1) . To evaluate the quality of published RCTs reported in Hepatitis monthly, we examined whether there was a change in the quality of reporting over time. Of the 610 articles published from 2010 to 2014, 583 nontrial or non-human trials were screened, and 27 trials were identified. Within these 27 trials, ten reports were without a control group and failed to meet our eligibility criteria. Therefore, 17 RCTs were identified. We completed a comprehensive quality assessment of each report using the short form of the CONSORT 2010 checklist (www.consortstatement.org) and a five-point quality assessment instrument called the Jadad scale (2) .
According to the Jadad score, the items including randomized, method of randomization, blinding, method of blinding, and dropouts/withdrawal of the Jadad scale were reported in 82.4%, 70.6%, 47%, 47%, and 94.1% of RCTs, respectively. According to this scale, the quality score of reporting was 3, 2. (Table 1 ).
In conclusion, in this assessment, we observed moderate quality scores in the reports of this journal. Training courses for reviewers, editorial use of standard reporting tools such as the CONSORT 2010 Statement, and consultation with methodologists can improve the quality of published RCTs. 
